- sodium alginate
- calcium carbonate
- sodium bicarbonate
GSL: General Sales Licence
This information is intended for use by health professionals
Gaviscon Strawberry Flavour Tablets.
Each tablet contains sodium alginate 250 mg, sodium hydrogen carbonate 133.5 mg, calcium carbonate 80 mg.
Excipient(s) with known effect:
For excipients, see Section 6.1.
Chewable tablet. (Tablet)
Pale pink, circular, flat with bevelled edges with the odour and flavour of strawberry.
Treatment of symptoms of gastro-oesophageal reflux such as acid regurgitation, heartburn and indigestion, for example, following meals or during pregnancy.
For oral administration, after being thoroughly chewed.
Adults and children 12 years and over: Two to four tablets after meals and at bedtime.Children under 12 years: Should be given only on medical advice. Elderly: No dose modifications necessary for this age group. Hepatic Impairment: No dose modification necessary.
Renal Insufficiency: Caution if highly restricted salt diet is necessary (see section 4.4).
This medicinal product is contraindicated in patients with known or suspected hypersensitivity to the active substances or to any of the excipients.
If symptoms do not improve after 7 days, the clinical situation should be reviewed.
This medicinal product contains 254.84 mg (11.08 mmol) of sodium per four-tablet dose, equivalent to 12.74% of the WHO recommended maximum daily intake for sodium. The maximum daily dose of this product is equivalent to 50.96 % of the WHO adult recommended maximum daily intake for sodium. This product is considered high in sodium. This should be particularly taken into account for those on a low salt diet (e.g. in some cases of congestive heart failure and renal impairment).
Each four-tablet dose contains 320 mg (3.2 mmol) of calcium carbonate. Care needs to be taken in treating patients with hypercalcaemia, nephrocalcinosis and recurrent calcium containing renal calculi.
Due to its aspartame content this product should not be given to patients with phenylketonuria.
A time-interval of 2 hours should be considered between Gaviscon intake and the administration of other medicinal products, especially tetracyclines, digoxine, fluoroquinolone, iron salt, ketoconazole, neuroleptics, thyroid hormones, penicillamine, beta-blockers (atenolol, metoprolol, propanolol), glucocorticoid, chloroquine, biphosphonates (diphosphonates) and estramustine. See also 4.4.
Clinical studies in more than 500 pregnant women as well as a large amount of data from post-marketing experience indicate no malformative nor feto/ neonatal toxicity of the active substances.
Gaviscon can be used during pregnancy, if clinically needed.
No effects of the active substances have been shown in breastfed newborns/infants of treated mothers. Gaviscon can be used during breast-feeding.
Pre-clinical investigations have revealed alginate has no negative effect on parental or offspring fertility or reproduction.
Clinical data do not suggest that Gaviscon has an effect on human fertility.
Adverse reactions have been ranked under headings of frequency using the following convention: very common (1/10), common (1/100 and <1/10), uncommon (1/1000 and <1/100), rare (1/10,000 and <1/1000), very rare (< 1/10,000) and not known (cannot be estimated from the available data).
System Organ Class
Immune System Disorders
Anaphylactic and anaphylactoid reactions. Hypersensitivity reactions such as urticaria.
Respiratory, Thoracic and Mediastinal Disorders
Respiratory effects such as bronchospasm.
Reporting of Suspected Adverse Reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Symptoms are likely to be minor; some abdominal discomfort may be experienced.
In the event of overdose symptomatic treatment should be given.
Pharmacotherapeutic classification: A02E A01 Anti-regurgitant.
On ingestion Gaviscon Strawberry 250 mg Tablets react rapidly with gastric acid to form a raft of alginic acid gel having a near neutral pH and which floats on the stomach contents, quickly and effectively impeding gastro-oesophageal reflux, for up to 4 hours. In severe cases the raft itself may be refluxed into the oesophagus, in preference to the stomach contents, and exert a demulcent effect.
The mode of action of Gaviscon Strawberry Flavour Tablets is physical and does not depend on absorption into the systemic circulation.
No pre-clinical findings of any relevance to the prescriber have been reported.
Xylitol and Carmellose sodium
Red iron oxide
Strawberry cream flavour (Strawberry cream PHS-048481)
Ingredients of the strawberry cream flavour:
Modified starch E1450
Propylene glycol E1520
Do not store above 25°C.
Unprinted, glass-clear, thermoformable laminate of uPVC/PE/PVdC with aluminium foil lidding blisters packed into cartons.
Pack sizes: 2, 4, 6, 8,16, 24, 32, 48, 60, 64, 72, 80.
Pack sizes 8, 12, 16, 32.
Not all pack sizes may be marketed.
No special instructions.
Reckitt Benckiser Healthcare (UK) Limited,Dansom Lane, Hull, HU8 7DS, United Kingdom.
RB Consumer Relations, PO Box 4644, SLOUGH, SL1 0NS, UK
0333 2005 345
0333 2005 345
0333 2005 345